Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0E5YG
|
||||
| Former ID |
DCL000454
|
||||
| Drug Name |
AZD1236
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Chronic obstructive pulmonary disease [ICD9: 490-492, 494-496; ICD10:J40-J44, J47] | Discontinued in Phase 2 | [1], [2] | ||
| Company |
AstraZeneca
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C15H19ClN4O5S
|
||||
| InChI |
InChI=1S/C15H19ClN4O5S/c1-15(13(21)18-14(22)19-15)9-26(23,24)20-6-4-11(5-7-20)25-12-3-2-10(16)8-17-12/h2-3,8,11H,4-7,9H2,1H3,(H2,18,19,21,22)/t15-/m1/s1
|
||||
| InChIKey |
SFJFBTPHDHUUPU-OAHLLOKOSA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | MMP-12 | Target Info | Inhibitor | [3] | |
| NetPath Pathway | IL1 Signaling Pathway | ||||
| IL5 Signaling Pathway | |||||
| Pathway Interaction Database | Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling | ||||
| Reactome | Collagen degradation | ||||
| Degradation of the extracellular matrix | |||||
| WikiPathways | TGF beta Signaling Pathway | ||||
| Degradation of collagen | |||||
| Matrix Metalloproteinases | |||||
| References | |||||
| REF 1 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7844). | ||||
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026714) | ||||
| REF 3 | Clinical pipeline report, company report or official report of AstraZeneca (2009). | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.